Acquisition Announced
Bayer acquisition of Perfuse Therapeutics
US$300m consideration
Announced 6 May 2026
Advisers
Perfuse Therapeutics
Target
- Legal adviser
- Goodwin

Team: Mitch Bloom, Rob Dzialo, Adam Dilluvio, Tim Ayotte, Dylan Miller, Ben Colao, Ankit Gupta, Noelle Dubiansky, Elizabeth Mulkey, Arman Oruc, Kevin Walsh, Theresa Kavanaugh, April Sun, Grace Wirth, Dasol Lee, Brian Mukherjee, Laura Conway, Justin Pierce, James Oh, Gozde Guckaya, Justin Shields, Dan Karelitz
Bayer
Acquirer
Not disclosed
- Target
- Perfuse Therapeutics
- Acquirer
- Bayer
- Target based in
- United States
- Buyer based in
- Germany
- Sector
- Biotech
- Tags
- Biotech, Ophthalmology, Drug Development
In the league tables
Similar deals
- Tarsus Pharmaceuticals acquisition of Alkeus Pharmaceuticals Aug 2026 · US$450m · Biotech
- Gyre Therapeutics acquisition of Cullgen Mar 2026 · US$300m · Biotech
- Dimerix acquisition of MTX652 Jul 2026 · US$292m · Biotech
- Eli Lilly and Company acquisition of CrossBridge Bio Apr 2026 · US$300m · Biotech
- BioMarin Pharmaceutical acquisition of Alesta Therapeutics Aug 2026 · US$275m · Biotech
Sources
- 6 May 2026 Goodwin Advises Perfuse Therapeutics on $2.45 Billion Acquisition by Bayer goodwinlaw.com